Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Shepherd

Showing results (21-30 of 105) with videos related to

Pageof 11
Sort By:
Cardiology|March 17, 2007
Safety of rosuvastatin: update on 16,876 rosuvastatin-treated patients in a multinational clinical trial programJames Shepherd, Donald G Vidt, Elinor Miller, et al.
The American Journal of Cardiology|October 3, 2002
Factors affecting low-density lipoprotein and high-density lipoprotein cholesterol response to pravastatin in the West Of Scotland Coronary Prevention Study (WOSCOPS)Leanne Streja, Chris J Packard, James Shepherd, et al.
Journal of Hepatology|May 11, 2021
Non-epidemic HCV genotypes in low- and middle-income countries and the risk of resistance to current direct-acting antiviral regimensRajiv Shah, Lucrece Ahovegbe, Marc Niebel, et al.
Current Medical Research and Opinion|August 25, 2004
Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-CM John Chapman, Gerd Assmann, Jean-Charles Fruchart, et al.
The American Journal of Cardiology|March 21, 2003
Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goalsJames Shepherd, Donald B Hunninghake, Philip Barter, et al.
Annals of Internal Medicine|April 21, 2010
Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trialRobert J Glynn, Wolfgang Koenig, Børge G Nordestgaard, et al.
Atherosclerosis. Supplements|November 9, 2004
Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. 2003James Shepherd, Donald B Hunninghake, Philip Barter, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 7, 2007
Competitive release and facilitation of drug-resistant parasites after therapeutic chemotherapy in a rodent malaria modelAndrew R Wargo, Silvie Huijben, Jacobus C de Roode, et al.
The New England Journal of Medicine|October 12, 2007
Long-term follow-up of the West of Scotland Coronary Prevention StudyIan Ford, Heather Murray, Chris J Packard, et al.
Atherosclerosis|February 7, 2012
Renal safety of intensive cholesterol-lowering treatment with rosuvastatin: a retrospective analysis of renal adverse events among 40,600 participants in the rosuvastatin clinical development programEvan A Stein, Donald G Vidt, James Shepherd, et al.
Pageof 11

Showing results (21-30 of 105) with videos related to

Sort By:
Pageof 11
Cardiology|March 17, 2007
Safety of rosuvastatin: update on 16,876 rosuvastatin-treated patients in a multinational clinical trial programJames Shepherd, Donald G Vidt, Elinor Miller, et al.
The American Journal of Cardiology|October 3, 2002
Factors affecting low-density lipoprotein and high-density lipoprotein cholesterol response to pravastatin in the West Of Scotland Coronary Prevention Study (WOSCOPS)Leanne Streja, Chris J Packard, James Shepherd, et al.
Journal of Hepatology|May 11, 2021
Non-epidemic HCV genotypes in low- and middle-income countries and the risk of resistance to current direct-acting antiviral regimensRajiv Shah, Lucrece Ahovegbe, Marc Niebel, et al.
Current Medical Research and Opinion|August 25, 2004
Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-CM John Chapman, Gerd Assmann, Jean-Charles Fruchart, et al.
The American Journal of Cardiology|March 21, 2003
Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goalsJames Shepherd, Donald B Hunninghake, Philip Barter, et al.
Annals of Internal Medicine|April 21, 2010
Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trialRobert J Glynn, Wolfgang Koenig, Børge G Nordestgaard, et al.
Atherosclerosis. Supplements|November 9, 2004
Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. 2003James Shepherd, Donald B Hunninghake, Philip Barter, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 7, 2007
Competitive release and facilitation of drug-resistant parasites after therapeutic chemotherapy in a rodent malaria modelAndrew R Wargo, Silvie Huijben, Jacobus C de Roode, et al.
The New England Journal of Medicine|October 12, 2007
Long-term follow-up of the West of Scotland Coronary Prevention StudyIan Ford, Heather Murray, Chris J Packard, et al.
Atherosclerosis|February 7, 2012
Renal safety of intensive cholesterol-lowering treatment with rosuvastatin: a retrospective analysis of renal adverse events among 40,600 participants in the rosuvastatin clinical development programEvan A Stein, Donald G Vidt, James Shepherd, et al.
Pageof 11